Tags

Type your tag names separated by a space and hit enter

Polygenic Risk Score associated with specific symptom dimensions in first-episode psychosis.
Schizophr Res 2017; 184:116-121SR

Abstract

Recent Genome-Wide Association Studies (GWAS) have provided evidence for the involvement of a number of genetic variants in schizophrenia (SCZ). The objective of the current study was to examine the association between these variants and symptom dimensions, evaluated prospectively over a period of 24months, in a clinically well-characterized sample of individuals (n=241) with first-episode psychosis (FEP). The genetic variants were analyzed collectively as captured through a Polygenic Risk Score (PRS), calculated for each individual. At each evaluation time point (baseline, 1, 2, 6 and 24months), correlation analysis was conducted with PRS and symptom dimension scores assessed by the Positive and Negative Syndrome Scale (PANSS). We also examined the association of PRS with global symptom rating, depression, anxiety, social and occupational functioning as measured by widely used and well validated scales. At baseline, significant positive correlation was observed between PRS and the general psychopathology dimension of the PANSS but no associations were observed with the positive or negative symptom dimensions. Anxiety, assessed using the Hamilton Anxiety Rating Scale, was also significantly correlated with the PRS. No significant correlation was observed with other symptom dimensions or with the PANSS score at the later evaluations. These results provide novel evidence of an association between general psychopathology and PRS in young people with first episode psychosis. They also demonstrate that it is important to note the dynamic changes of symptoms over time when trying to refine the relationship between genetic factors and phenotypes.

Authors+Show Affiliations

Douglas Mental Health University Institute, 6875 LaSalle Blvd, Verdun, Quebec H4H 1R3, Canada; Department of Psychiatry, McGill University, Ludmer Research & Training Building, 1033 Pine Ave. West, Montreal, Quebec H3A 1A1, Canada. Electronic address: sarojini.sengupta@douglas.mcgill.ca.Douglas Mental Health University Institute, 6875 LaSalle Blvd, Verdun, Quebec H4H 1R3, Canada; Department of Psychiatry, McGill University, Ludmer Research & Training Building, 1033 Pine Ave. West, Montreal, Quebec H3A 1A1, Canada.Douglas Mental Health University Institute, 6875 LaSalle Blvd, Verdun, Quebec H4H 1R3, Canada; Department of Psychiatry, McGill University, Ludmer Research & Training Building, 1033 Pine Ave. West, Montreal, Quebec H3A 1A1, Canada.Department of Medicine, Université de Sherbrooke, Local E5-1283, Sherbrooke, Québec J1K 2R1, Canada.Douglas Mental Health University Institute, 6875 LaSalle Blvd, Verdun, Quebec H4H 1R3, Canada; Department of Psychiatry, McGill University, Ludmer Research & Training Building, 1033 Pine Ave. West, Montreal, Quebec H3A 1A1, Canada; Integrated Program in Neuroscience, McGill University, Room 141, Montreal Neurological Institute, 3801 University Street, Montreal, Quebec H3A 2B4, Canada.Douglas Mental Health University Institute, 6875 LaSalle Blvd, Verdun, Quebec H4H 1R3, Canada; Department of Psychiatry, McGill University, Ludmer Research & Training Building, 1033 Pine Ave. West, Montreal, Quebec H3A 1A1, Canada.Douglas Mental Health University Institute, 6875 LaSalle Blvd, Verdun, Quebec H4H 1R3, Canada; Department of Psychiatry, McGill University, Ludmer Research & Training Building, 1033 Pine Ave. West, Montreal, Quebec H3A 1A1, Canada.Douglas Mental Health University Institute, 6875 LaSalle Blvd, Verdun, Quebec H4H 1R3, Canada; Department of Psychiatry, McGill University, Ludmer Research & Training Building, 1033 Pine Ave. West, Montreal, Quebec H3A 1A1, Canada; Integrated Program in Neuroscience, McGill University, Room 141, Montreal Neurological Institute, 3801 University Street, Montreal, Quebec H3A 2B4, Canada; Department of Human Genetics, McGill University, Room N5-13, Stewart Biology Building, 1205 Dr. Penfield Ave., Montreal, Quebec H3A 1B1, Canada.

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

27916287

Citation

Sengupta, Sarojini M., et al. "Polygenic Risk Score Associated With Specific Symptom Dimensions in First-episode Psychosis." Schizophrenia Research, vol. 184, 2017, pp. 116-121.
Sengupta SM, MacDonald K, Fathalli F, et al. Polygenic Risk Score associated with specific symptom dimensions in first-episode psychosis. Schizophr Res. 2017;184:116-121.
Sengupta, S. M., MacDonald, K., Fathalli, F., Yim, A., Lepage, M., Iyer, S., ... Joober, R. (2017). Polygenic Risk Score associated with specific symptom dimensions in first-episode psychosis. Schizophrenia Research, 184, pp. 116-121. doi:10.1016/j.schres.2016.11.039.
Sengupta SM, et al. Polygenic Risk Score Associated With Specific Symptom Dimensions in First-episode Psychosis. Schizophr Res. 2017;184:116-121. PubMed PMID: 27916287.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Polygenic Risk Score associated with specific symptom dimensions in first-episode psychosis. AU - Sengupta,Sarojini M, AU - MacDonald,Kathleen, AU - Fathalli,Ferid, AU - Yim,Anita, AU - Lepage,Martin, AU - Iyer,Srividya, AU - Malla,Ashok, AU - Joober,Ridha, Y1 - 2016/12/02/ PY - 2016/08/25/received PY - 2016/11/21/revised PY - 2016/11/24/accepted PY - 2016/12/6/pubmed PY - 2018/3/27/medline PY - 2016/12/6/entrez KW - Anxiety KW - First-episode psychosis KW - General psychopathology KW - PANSS KW - Polygenic Risk Score KW - Schizophrenia SP - 116 EP - 121 JF - Schizophrenia research JO - Schizophr. Res. VL - 184 N2 - Recent Genome-Wide Association Studies (GWAS) have provided evidence for the involvement of a number of genetic variants in schizophrenia (SCZ). The objective of the current study was to examine the association between these variants and symptom dimensions, evaluated prospectively over a period of 24months, in a clinically well-characterized sample of individuals (n=241) with first-episode psychosis (FEP). The genetic variants were analyzed collectively as captured through a Polygenic Risk Score (PRS), calculated for each individual. At each evaluation time point (baseline, 1, 2, 6 and 24months), correlation analysis was conducted with PRS and symptom dimension scores assessed by the Positive and Negative Syndrome Scale (PANSS). We also examined the association of PRS with global symptom rating, depression, anxiety, social and occupational functioning as measured by widely used and well validated scales. At baseline, significant positive correlation was observed between PRS and the general psychopathology dimension of the PANSS but no associations were observed with the positive or negative symptom dimensions. Anxiety, assessed using the Hamilton Anxiety Rating Scale, was also significantly correlated with the PRS. No significant correlation was observed with other symptom dimensions or with the PANSS score at the later evaluations. These results provide novel evidence of an association between general psychopathology and PRS in young people with first episode psychosis. They also demonstrate that it is important to note the dynamic changes of symptoms over time when trying to refine the relationship between genetic factors and phenotypes. SN - 1573-2509 UR - https://www.unboundmedicine.com/medline/citation/27916287/Polygenic_Risk_Score_associated_with_specific_symptom_dimensions_in_first_episode_psychosis_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0920-9964(16)30549-7 DB - PRIME DP - Unbound Medicine ER -